Medarex' MDX-210 In Breast Cancer

26 May 1996

Medarex has presented data from two of its onging Phase I/II trials of MDX-210, which reveal promising activity in late-stage breast cancer patients. All patients enrolled into the studies had failed multiple courses of other anticancer regimens.

In a US study, patients were treated with multiple doses of MDX-210 in combination with G-CSF. Of 12 patients treated with a six-week course of the drug, three showed regression or stabilization of disease and went on to a second course, two patients reported relief of bone pain, one patient showed shrinkage in a lymph node metastasis, and another patient experienced significant bone marrow metastasis clearance which removed her dependency on transfusions.

A European study tested various doses of MDX-210 in a single-dose regimen with G-CSF. This study found that around one third of patients experienced stabilization of disease over a 60-day follow-up period. Larger Phase II trials of MDX-210 in advanced breast cancer patients should begin in the very near future, according to Medarex.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight